Salvage chemotherapy with amrubicin and platinum for relapsed thymic carcinoma: Experience in six cases

Medical Oncology

Volumn 27, Issue 2, 2010, Pages 392-396

  Koizumi, Tomonobu ^a   Agatsuma, Toshihiko ^a   Ichiyama, Takashi ^a   Yokoyama, Toshiki ^a   Ushiki, Atsuhito ^a   Komatsu, Yoshimichi ^a   Tanabe, Tsuyoshi ^a   Kobayashi, Takashi ^a   Yoshikawa, Sumiko ^a   Yasuo, Masanori ^a   Yamamoto, Hiroshi ^a   Kubo, Keishi ^a   Hachiya, Tsutomu ^b  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Suwa Red Cross Hospital   (Japan)

Author keywords

ADOC; Anthracycline; Chemotherapy; Neutropenia; Relapsed thymic carcinoma; Topoisomerase II inhibitor

Indexed keywords

AMRUBICIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; NEDAPLATIN; PACLITAXEL; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TRANSFUSION; BONE SCINTISCANNING; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DRUG EFFICACY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HEART VENTRICLE TACHYCARDIA; HERPES ZOSTER; HUMAN; LEUKOPENIA; LYMPH NODE BIOPSY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; THYMUS CANCER; TREATMENT RESPONSE; VIDEO ASSISTED THORACOSCOPIC SURGERY;

ADULT; AGED; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PLATINUM COMPOUNDS; RECURRENCE; SALVAGE THERAPY; THYMOMA;

EID: 77954697811     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9223-y     Document Type: Article

References (21)

1. Suster S, Rosai J. Thymic carcinoma. A clinicopathologic study of 60 cases. Cancer. 1991;67:1025-32. doi:10.1002/1097-0142 (19910215)67:4<1025:: AID-CNCR2820670427>3.0.CO;2-F.
2. Hsu CP, Chen CY, Hsu NY, Wang JH, Wang PY. Thymic carcinoma. Ten years' experience in twenty patients. J Thorac Cardiovasc Surg. 1994;107:615-20.
3. Takeda S, et al. Thymic carcinoma. Clinical institutional experience with 15 patients. Eur J Cardiothorac Surg. 2004;26:401-6. doi:10.1016/j.ejcts.2004. 03.043. (Pubitemid 39024667)
4. Yoh K, et al. Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma. Cancer. 2004;98:926-31. doi:10.1002/cncr. 11606.
5. Koizumi T, et al. Chemotherapy for advanced thymic carcinoma Clinical responsive for cisplatin, doxorubicin, vincristine and cyclophosphamide (ADOC chemotherapy). Am J Clin Oncol.2002;25:266-8. doi:10.1097/00000421-200206000- 00012. (Pubitemid 34602548)
6. Kitami A, Suzuki T, Kamio Y, Suzuki S. Chemotherapy of thymiccarcinoma: analysis of seven cases and review of the literature. Jpn J Clin Oncol. 2001;31:601-4. doi:10.1093/jjco/hye136.
7. Yanagawa H, et al. Thymic carcinoma treated with intensive chemotherapy and radiation. Anticancer Res. 1995;15:1485-9.
8. Carlson RW, Dorfman RF, Sikic BI. Successful treatment of metastatic thymic carcinoma with cisplatin, vinblastine, bleomycin, and etoposide chemotherapy. Cancer. 1990;66:2092-4. doi: 10.1002/1097-0142(19901115)66: 10<2092::AID-CNCR2820661 008[3.0.CO;2-1.
9. Ohe Y, et al. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines. Cancer Res. 1989;49:4098-102.
10. Hanada M, et al. A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. Jpn J Cancer Res. 1998;89:1229-38.
11. Hanada M, Noguchi T, Yamaoka T. Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo. Cancer Sci. 2007;98:447-54. doi:10.1111/j.1349-7006. 2007.00404.x. (Pubitemid 46195619)
12. Onoda S, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol. 2006;24:5448-53. doi: 10.1200/JCO.2006.08.4145. (Pubitemid 46623179)
13. Ohe Y, et al. Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer. Ann Oncol. 2005;16:430-6. doi:10.1093/annonc/mdi081. (Pubitemid 40458320)
14. Ikeda J, et al. Phase I study of amrubicin hydrochloride and cisplatin in patients previously treated for advanced non-small cell lung cancer. Jpn J Clin Oncol. 2006;36:12-6. doi:10.1093/ jjco/hyi217.
15. Inoue A, et al. A phase I study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer. J Thorac Oncol. 2006;1:551-5. doi:10.1097/01243894-200607000- 00009. (Pubitemid 47181403)
16. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981;48:2485-92. doi:10.1002/1097-0142(19811201)48: 11<2485::AID-CNCR2820481123>3.0.CO;2-R.
17. National Cancer Institute: Common Toxicity Criteria (CTC) v 2.0. http://ctep.cancer.gov/reporting/ctc.html
18. Therasse P, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16. doi:10.1093/jnci/92.3.205. (Pubitemid 30099779)
19. Komatsu Y, et al. Salvage chemotherapy with carboplatin and paclitaxel for cisplatin-resistant thymic carcinoma-three cases. Anticancer Res. 2006;26:4851-5.
20. Suzuki T, Minamide S, Iwasaki T, Yamamoto H, Kanda H. Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin. Invest New Drugs. 1997;15:219-25. doi: 10.1023/A:1005862730941. (Pubitemid 27453876)
21. Noda T, Watanabe T, Kohda A, Hosokawa S, Suzuki T. Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in dogs. Invest New Drugs. 1998;16:121-8. doi:10.1023/A:10060 88907271.